| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $278K | -49.1% | -87.8% |
| SG&A Expense | $1.8M | +39.1% | +14.7% |
| Operating Income | -$2.1M | -13.1% | +45.8% |
| Net Income | -$2.1M | -13.3% | +44.6% |
| EPS (Basic) | -$0.34 | +46.9% | +86.1% |
| EPS (Diluted) | -$0.34 | +46.9% | +86.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $7.6M | +239.4% | +59.4% |
| Current Assets | $7.7M | +204.3% | +46.6% |
| Total Assets | $7.7M | +204.3% | +46.6% |
| Current Liabilities | $1.5M | -28.6% | -30.9% |
| Total Liabilities | $1.5M | -28.6% | -30.9% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.7M | — | — |
| Financing Cash Flow | $9.7M | — | — |
| $6.2M |
| +1575.4% |
| +104.0% |